0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

Whither Interferon for Myeloma and Other Hematologic Malignancies?

Raymond Alexanian, MD; and Donna Weber, MD
[+] Article and Author Information

University of Texas Houston, TX 77030 Grant Support: In part by the Robert Hompe Myeloma Research Fund. Requests for Reprints: Raymond Alexanian, MD, University of Texas M.D. Anderson Cancer Center, Box 001, 1515 Holcombe Boulevard, Houston, TX 77030. Current Author Addresses: Drs. Alexanian and Weber: University of Texas M.D. Anderson Cancer Center, Box 001, 1515 Holcombe Boulevard, Houston, TX 77030.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(2):264-265. doi:10.7326/0003-4819-124-2-199601150-00012
Text Size: A A A

Multiple myeloma is one of the common hematologic malignancies now affecting approximately 12 500 persons in the United States each year. The number of patients with this condition continues to increase as a result of more frequent screening with electrophoresis and more diagnoses among a progressively aging population. Despite intensive study of many treatments, including those supported by stem cell transplantation, overall survival has not improved, and the disease remains incurable [1]. Accordingly, the best available strategy has been to achieve a high frequency of remission that can be sustained for several years, and then to repeatedly control relapsing disease with a series of effective and well-tolerated treatments.

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Interferon therapy of hematologic malignancies. Cancer Treat Res 1998;94():1-21.
Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002;29(3 Suppl 7):18-26.

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)